Sequential immunological analysis of HBV/HCV co-infected patients during Peg-IFN/RBV therapy

被引:6
|
作者
Kondo, Yasuteru [1 ]
Ueno, Yoshiyuki [1 ]
Ninomiya, Masashi [1 ]
Tamai, Keiichi [1 ]
Tanaka, Yasuhito [2 ]
Inoue, Jun [1 ]
Kakazu, Eiji [1 ]
Kobayashi, Koju
Kimura, Osamu [1 ]
Miura, Masahito [3 ]
Yamamoto, Takeshi [4 ]
Kobayashi, Tomoo [5 ]
Igarashi, Takehiko [6 ]
Shimosegawa, Tooru [1 ]
机构
[1] Tohoku Univ, Grad Sch Med, Div Gastroenterol, Aoba Ku, Sendai, Miyagi 980, Japan
[2] Nagoya City Univ, Sch Med, Virol & Liver Unit, Nagoya, Aichi 467, Japan
[3] S Miyagi Med Ctr, Dept Gastroenterol, Oogawara, Miyagi, Japan
[4] Tohoku Kosei Nenkin Hosp, Dept Gastroenterol, Sendai, Miyagi, Japan
[5] Tohoku Rosai Hosp, Dept Hepatol, Sendai, Miyagi, Japan
[6] Osaki Citizen Hosp, Dept Gastroenterol, Osaki, Japan
关键词
Dual infection; HBV; HCV; Immunopathogenesis; HEPATITIS-B-VIRUS; REGULATORY T-CELLS; HEPATOCELLULAR-CARCINOMA; COINFECTED PATIENTS; DUAL INFECTION; GENOTYPE-B; VIRAL INTERACTIONS; IMMUNE-RESPONSES; INTERFERON; RIBAVIRIN;
D O I
10.1007/s00535-012-0596-x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The immunopathogenesis of dual chronic infection with hepatitis B virus and hepatitis C virus (HBV/HCV) remains unclear. The in vivo suppressive effects of each virus on the other have been reported. In this study we aimed to analyze the virological and immunological parameters of HBV/HCV coinfected patients during pegylated interferon/ribavirin (Peg-IFN/RBV) therapy. One patient with high HBV-DNA and high HCV-RNA titers (HBV-high/HCV-high) and 5 patients with low HBV-DNA and high HCV-RNA titers (HBV-low/HCV-high) were enrolled. Twenty patients monoinfected with HBV and 10 patients monoinfected with HCV were enrolled as control subjects.. In vitro cultures of Huh 7 cells with HBV/HCV dual infection were used to analyze the direct interaction of HBV/HCV. Direct interaction of HBV clones and HCV could not be detected in the Huh-7 cells. In the HBV-high/HCV-high-patient, the HCV-RNA level gradually declined and HBV-DNA gradually increased during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased at 1 month of Peg-IFN/RBV-therapy, but HBV-specific IFN-gamma-secreting cells were not increased and HBV-specific interleukin (IL)-10 secreting cells were increased. The level of HBV- and HCV-specific IFN-gamma-secreting cells in the HBV-high/HCV-high-patient was low in comparison to that in the HBV- or HCV-monoinfected patients. In the HBV-low/HCV-high-patient, HCV-RNA and HBV-DNA rapidly declined during Peg-IFN/RBV therapy. Activated CD4- and CD8-positive T cells were increased, and HBV- and HCV-specific IFN-gamma-secreting cells were also increased during Peg-IFN/RBV-therapy. The immunological responses of the HBV-high/HCV-high patient were low in comparison to the responses in HBV and HCV monoinfected patients. Moreover, the response of immune cells in the HBV-high/HCV-high patient during Peg-IFN/RBV therapy was insufficient to suppress HBV and HCV.
引用
收藏
页码:1323 / 1335
页数:13
相关论文
共 50 条
  • [31] ANALYSIS OF THE OPTIMAL TVR DOSE PER WEIGHT JUDGING FROM ANEMIA DURING PEG-IFN/RBV/TVR COMBINATION THERAPY
    Karino, Y.
    Ozeki, I.
    Hige, S.
    Toyota, J.
    Imamura, M.
    Tsuge, M.
    Chayama, K.
    Akuta, N.
    Suzuki, F.
    Kumada, H.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S338 - S338
  • [32] Rapid and early virological response to chronic hepatitis C treatment with IFN α2b or PEG-IFN α2b plus ribavirin in HIV/HCV co-infected patients
    Payan, Christopher
    Pivert, Adeline
    Morand, Patrice
    Fafi-Kremer, Samira
    Carrat, Fabrice
    Pol, Stanislas
    Cacoub, Patrice
    Perronne, Christian
    Lunel, Francoise
    GUT, 2007, 56 (08) : 1111 - 1116
  • [33] Coffee consumption and reduced self-reported side effects in HIV-HCV co-infected patients during PEG-IFN and ribavirin treatment: Results from ANRS CO13 HEPAVIH
    Carrieri, M. Patrizia
    Cohen, Julien
    Salmon-Ceron, Dominique
    Winnock, Maria
    JOURNAL OF HEPATOLOGY, 2012, 56 (03) : 745 - 747
  • [35] Long-term clinical benefit of Peg-IFNα and NAs sequential antiviral therapy on HBV related HCC
    Qi, Wen-Qian
    Zhang, Qian
    Wang, Xu
    Xu, Yan
    Zhao, Ping
    Guo, Hong-Hua
    Zhou, Chang-Yu
    Sun, Yu
    Liu, Lin
    Wang, Jiang-Bin
    NEOPLASMA, 2021, 68 (01) : 200 - 207
  • [36] Long term immunological perturbations post DAA therapy in chronic HCV/HIV co-infected patients
    Moretti, Sonia
    Mancini, Flavia
    Borsetti, Alessandra
    BIOCELL, 2022, 46 (12) : 2695 - 2699
  • [37] Predictive value of early virological reduction (EVR) in the response at 24 weeks (W) of HCV treatment with Peg-interferon (Peg-IFN) & ribavirine (RBV) in HIV-infected patients (P)
    Ballesteros, AL
    Franco, S
    Fuster, D
    Martinez, MA
    Acosta, L
    Salas, A
    Rey-Joly, C
    Tor, J
    Planas, R
    Clotet, B
    Tural, C
    JOURNAL OF HEPATOLOGY, 2003, 38 : 125 - 126
  • [38] Final results of patients treated with Peg-interferon-alfa-2a (Peg-IFN) and ribavirin (RBV) follow-on therapy after 28-day treatment with the Hepatitis C protease inhibitor telaprevir (VX-950), Peg-IFN and RBV
    Rodriguez-Torres, Maribel
    Lawitz, Eric J.
    McHutchison, John G.
    HEPATOLOGY, 2007, 46 (04) : 314A - 315A
  • [39] Influence of interferon (IFN)-based therapy on liver fibrosis progression (LFP) in HIV/HCV co-infected patients
    Benhamou, Yves
    Valentin, Marc Antoine
    Dominguez, Stephanie
    Varastet, Marina
    Zin, Adeline
    Katlama, Christine
    Poynard, Thierry
    HEPATOLOGY, 2007, 46 (04) : 849A - 849A
  • [40] Increasing of Ribavirin (RBV) doses improves the sustained virological response (SVR) in hepatits C virus (HCV) patients partial responders to pegylated interferon (Peg-IFN) and RBV
    Conti, Fabio
    Vukotic, Ranka
    Lorenzini, Stefania
    Riili, Anna
    Cursaro, Carmela
    Scuteri, Alessandra
    Loggi, Elisabetta
    Bernardi, Mauro
    Andreone, Pietro
    HEPATOLOGY, 2012, 56 : 1048A - 1049A